Ascending Doses of Ceralasertib in Combination With Chemotherapy and/​or Novel Anti Cancer Agents Eligibility Criteria

Principal Inclusion criteria:

  • Aged at least 18
  • The presence of a solid malignant tumour that is not considered appropriate for further standard treatment
  • Female participant with histologically/cytologically confirmed, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Eligible histologies include high grade serous and high grade endometrioid. Ineligible histologies include low grade serous, low grade endometrioid, mucinous and carcinosarcoma
  • Module 5 All: Ovarian fallopian tube or primary peritonial cancer, previous treatment with PARP inhibitor, platinum-sensitive relapsed ovarian cancer
  • Module 5 Part B: known or suspected BRCA mutation, PALB2 mutation, RAD51C/D mutation or HRD positive status

Principal exclusion criteria

  • A diagnosis of ataxia telangiectasia
  • Prior exposure to an ATR inhibitor
  • Bad reaction to ceralasertib
  • Module 5: Known hypersensitivity to PARP including AZD5305